Novartis plans to present late-breaking data from multiple pivotal cardiovascular studies at the 2026 European Society of Cardiology Congress. The presentations include head-to-head Phase IV results for Leqvio in LDL-C management and new analyses on bleeding risk for abelacimab in atrial fibrillation. These data may influence future treatment guidelines and physician use of Novartis cardiovascular therapies. Investors will watch whether Leqvio meets LDL-C targets versus bempedoic acid and whether AZALEA TIMI 71 shows a meaningfully different total bleeding pattern for abelacimab compared with rivaroxaban.
Novartis AGPivotal cardiovascular data presentations may influence guidelines and physician use, but outcomes are uncertain.
